Collectively, these data suggest that promoting PKM2 pyruvate kinase activity via forming PKM2 tetramer by TEPP-46 may not significantly improve colitis, whereas a simultaneous inhibition on both dimerization and tetramerization by Shikonin significantly improved colitis. The gene discussed is PKM; the disease is colitis.